dm+d

391632007

Refrigerated Storage

LemtradaSanofi Genzyme

Sanofi Genzyme
Lemtrada
12mg concentration for solution for infusion

Contact Sanofi Genzyme in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

13 September 2021
London MI Sevice

New Medicines

LemtradaRelapsing-remitting multiple sclerosis in children aged 10 to 18 years

Information

Lemtrada
Licence extension / variation
Sanofi
Sanofi

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
None

Category

Monoclonal CD52 antibody
Prevalence of MS in the UK in 2010 was 285.8 per 100,000 in women and 113.1 per 100,000 in men [1]. Fewer than one in every 100 people with MS will experience symptoms before the age of 10 but between two and five in every 100 people experience their first symptoms before the age of 18 [2].
Relapsing-remitting multiple sclerosis in children aged 10 to 18 years
Intravenous infusion